Coadministration of low-dose urokinase and abciximab in thrombolysis for lower limb ischemia. a safety study

Thromb Res. 2001 Sep 30:103 Suppl 1:S143-9. doi: 10.1016/s0049-3848(01)00311-5.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Abciximab
  • Aged
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / therapeutic use
  • Arterial Occlusive Diseases / drug therapy
  • Catheterization
  • Drug Therapy, Combination
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / standards
  • Humans
  • Immunoglobulin Fab Fragments / administration & dosage*
  • Immunoglobulin Fab Fragments / therapeutic use
  • Ischemia / drug therapy*
  • Leg / blood supply
  • Leg / pathology
  • Male
  • Middle Aged
  • Pilot Projects
  • Recurrence
  • Thrombolytic Therapy / methods
  • Thrombolytic Therapy / standards
  • Treatment Outcome
  • Urokinase-Type Plasminogen Activator / administration & dosage*
  • Urokinase-Type Plasminogen Activator / standards
  • Vascular Patency / drug effects

Substances

  • Antibodies, Monoclonal
  • Fibrinolytic Agents
  • Immunoglobulin Fab Fragments
  • Urokinase-Type Plasminogen Activator
  • Abciximab